- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.10. | Nuvig halts development of lead drug for rare autoimmune disease | ||
| 06.10. | How NIH's Kleinstreuer reduces animal tests without 'backlash' | ||
| 06.10. | Mimetic's peptide shows promise in reducing neuropathic pain | ||
| 06.10. | ArriVent's phase 3 lung cancer trial flops, sinking stock | ||
| 06.10. | Kairos seizes moment to push cancer asset into earlier setting | ||
| 06.10. | Forbion's 'landmark' €2.3B fundraise to benefit 30 biotechs | ||
| 06.10. | AstraZeneca hopes for 'amazing things' from Kendall Square R&D center | ||
| 06.10. | TRex Bio eyes $111M IPO, as Retension Pharma and Lycia also look to Nasdaq | ||
| 05.10. | Gate CEO sees expanded $870M Lilly pact as 'vote of confidence' | ||
| 05.10. | Trio of scientists win Nobel Prize for neuron light switch work | ||
| 05.10. | 4 Criteria for Choosing the Right Biologics CDMO | ||
| 05.10. | Genmab ph. 2 data spur claim ADC 'clearly superior' to Elahere | ||
| 05.10. | CSL pays $355M to co-develop Alentis' ph. 2-stage fibrosis drug | ||
| 05.10. | There Is No Such Thing as a Typical Biotech | ||
| 02.10. | Novartis pens $7.8B deal for Abogen's in vivo autoimmune TCE | ||
| 02.10. | Bayer taps new chief medical officer-Chutes & Ladders | ||
| 02.10. | NAMs: Why proving repeatability is the next hurdle for widespread adoption | ||
| 02.10. | Adecto blames 'risk-adverse funding environment' for closing | ||
| 01.10. | Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 | ||
| 01.10. | Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D | ||
| 30.09. | Lilly raises diabetes weight loss bar with amylin-Zepbound combo | ||
| 30.09. | Beam Therapeutics sues base editing rival, claims former scientist stole secrets | ||
| 30.09. | Merck's anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial | ||
| 30.09. | GSK continues to stock up on Wave's RNA drugs with liver-focused program | ||
| 30.09. | Connect's Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.